SNHG9 exhibits a dual role in cancer progression: it has been shown to promote cell proliferation, migration, and invasion in hepatocellular carcinoma cells [28], induce hepatoblastoma tumorigenesis via miR-23a-5p/WNT3a Axis [29], and be associated with with poor survival and immune infiltrations in prostate cancer [30]; in contrast it inhibits ovarian cancer progression by sponging microRNA-214-5p [31]. Here, WNT3A is linked to ovarian carcinoma.